RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zealand Pharma A/S Stock

Zealand Pharma A/S Equity 2025

Zealand Pharma A/S Equity

8.62 B DKK

Ticker

ZEAL.CO

ISIN

DK0060257814

WKN

A0YJW7

In 2025, Zealand Pharma A/S's equity was 8.62 B DKK, a 440.97% increase from the 1.59 B DKK equity in the previous year.

Zealand Pharma A/S Aktienanalyse

What does Zealand Pharma A/S do?

Zealand Pharma A/S is a biopharmaceutical company specializing in the discovery and development of therapeutics, particularly in the field of diabetes, gastrointestinal, and metabolic diseases. The company aims to improve the quality of life for patients with chronic conditions. Zealand Pharma's business model is based on the discovery, development, and commercialization of novel peptide-based therapeutics, utilizing their own technology platform and partnering with pharmaceutical industry collaborators. Their portfolio includes innovative product candidates such as the diabetes treatment Adlyxin and Lixisenatide, both GLP-1 agonists developed in collaboration with Sanofi. They also have products for the treatment of gastrointestinal and heart diseases. Zealand Pharma has a wide pipeline of product candidates at various stages of development, including for the treatment of obesity, fatty liver diseases, and other metabolic conditions. The company works closely with partners such as Sanofi, Boehringer Ingelheim, and Roche. Zealand Pharma is listed on NASDAQ OMX Copenhagen and employs over 200 people in Denmark and the USA. Overall, Zealand Pharma is an innovative biopharmaceutical company with a diverse portfolio of product candidates, focused on collaboration to accelerate product development and improve the quality of life for patients with chronic conditions. Zealand Pharma A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Zealand Pharma A/S's Equity

Zealand Pharma A/S's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Zealand Pharma A/S's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Zealand Pharma A/S's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Zealand Pharma A/S's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Zealand Pharma A/S’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Zealand Pharma A/S stock

What is the equity of Zealand Pharma A/S this year?

Zealand Pharma A/S has equity of 8.62 B DKK this year.

What was the equity of Zealand Pharma A/S compared to the previous year?

The equity of Zealand Pharma A/S has increased/decreased by 440.97% increased compared to the previous year.

What impact does a high equity have on investors of Zealand Pharma A/S?

A high equity is advantageous for investors of Zealand Pharma A/S as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Zealand Pharma A/S?

A low equity can be a risk for investors of Zealand Pharma A/S, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Zealand Pharma A/S affect the company?

An increase in equity of Zealand Pharma A/S can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Zealand Pharma A/S affect the company?

A reduction in equity of Zealand Pharma A/S can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Zealand Pharma A/S?

Some factors that can affect the equity of Zealand Pharma A/S include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Zealand Pharma A/S so important for investors?

The equity of Zealand Pharma A/S is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Zealand Pharma A/S take to change the equity?

To change equity, Zealand Pharma A/S can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Zealand Pharma A/S pay?

Over the past 12 months, Zealand Pharma A/S paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zealand Pharma A/S is expected to pay a dividend of 0 DKK.

What is the dividend yield of Zealand Pharma A/S?

The current dividend yield of Zealand Pharma A/S is .

When does Zealand Pharma A/S pay dividends?

Zealand Pharma A/S pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zealand Pharma A/S?

Zealand Pharma A/S paid dividends every year for the past 0 years.

What is the dividend of Zealand Pharma A/S?

For the upcoming 12 months, dividends amounting to 0 DKK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zealand Pharma A/S located?

Zealand Pharma A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zealand Pharma A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zealand Pharma A/S from 7/9/2025 amounting to 0 DKK, you needed to have the stock in your portfolio before the ex-date on 7/9/2025.

When did Zealand Pharma A/S pay the last dividend?

The last dividend was paid out on 7/9/2025.

What was the dividend of Zealand Pharma A/S in the year 2024?

In the year 2024, Zealand Pharma A/S distributed 0 DKK as dividends.

In which currency does Zealand Pharma A/S pay out the dividend?

The dividends of Zealand Pharma A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zealand Pharma A/S

Our stock analysis for Zealand Pharma A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zealand Pharma A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.